Intravenous Iron to Improve Symptoms, Quality of Life and Exercise Capacity in HFpEF With Iron Deficiency

A phase 2 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 150 participants.

Also called NCT07643818

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07643818
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Jersey (from the registry)
Registry status
  • Enrolling by invitation (from the registry)

Technical summary

Registry record NCT07643818. Randomized; double masking; primary purpose treatment. Start 2026-06-19 (actual); primary completion 2029-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Intravenous Iron to Improve Symptoms, Quality of Life and Exercise Capacity in HFpEF With Iron Deficiency
Acronym
ISLE HFpEF
Intervention (Drug)
Ferric Derisomaltose
Intervention (Drug)
Placebo
Lead sponsor
Government of Jersey (class: other government)
Collaborator
University of Oxford (class: other)

Record details

Record id
cardio:ct-nct07643818
Content hash
8ff15b53511609942e27d5bf9190dabb842c4248fc6785269c8a17656282a154